Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Cancer Cell

Volumn 2, Issue 2, 2002, Pages 127-137

  Agus, David B ^a   Akita, Robert W ^b   Fox, William D ^a   Lewis, Gail D ^b   Higgins, Brian ^c,d   Pisacane, Paul I ^b   Lofgren, Julie A ^b,e   Tindell, Charles ^a   Evans, Douglas P ^a   Maiese, Krista ^a   Scher, Howard I ^c   Sliwkowski, Mark X ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b GENENTECH INC   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

^e AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; PERTUZUMAB; TRASTUZUMAB; ANDROGEN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIGAND; MESSENGER RNA; MONOCLONAL ANTIBODY; NEU DIFFERENTIATION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; LIGAND BINDING; MALE; MOUSE; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN EXPRESSION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STEREOCHEMISTRY; TUMOR GROWTH; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; NOTE; PATHOLOGY; PROTEIN BINDING; TIME; XENOGRAFT;

ANDROGENS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; MALE; MICE; NEOPLASM TRANSPLANTATION; NEUREGULIN-1; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 19044380618     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00097-1     Document Type: Article

References (74)

1. Adam, R.M., Borer, J.G., Williams, J., Eastham, J.A., Loughlin, K.R., and Freeman, M.R. (1999). Amphiregulin is coordinately expressed with heparin-binding epidermal growth factor-like growth factor in the interstitial smooth muscle of the human prostate. Endocrinology 140, 5866-5875.
2. Agus, D.B., Cordon-Cardo, C., Fox, W., Drobnjak, M., Koff, A., Golde, D., and Scher, H.I. (1999a). Prostate cancer cell cycle regulators: response to androgen withdrawl and development of androgen independence. J. Natl. Cancer Inst. 91, 1869-1876.
3. Agus, D.B., Cordon-Cardo, C., Fox, W., Drobnjak, M., Koff, A., Golde, D.W., and Scher, H.I. (1999b). Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J. Natl. Cancer Inst. 91, 1869-1876.
4. Agus, D.B., Scher, H.I., Higgins, B., Fox, W.D., Heller, G., Fazzari, M., Cordon-Cardo, C., and Golde, D.W. (1999c). Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res. 59, 4761-4764.
5. Agus, D.B., Akita, R.W., Fox, W.D., Lofgren, J.A., Higgins, B., Maiese, K., Scher, H.I., and Sliwkowski, M.X. (2000). A potential role for activated HER-2 in prostate cancer. Semin. Oncol. 27, 76-83.
6. Alimandi, M., Romano, A., Curia, M.C., Muraro, R., Fedi, P., Aaronson, S.A., Di Fiore, P.P., and Kraus, M.H. (1995). Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10, 1813-1821.
7. Arteaga, C.L. (2001). The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J. Clin. Oncol. 19, 32S-40S.
8. Baselga, J., and Averbuch, S.D. (2000). ZD1839 ('Iressa') as an anticancer agent. Drugs 60, 33-40.
9. Baselga, J., Norton, L., Albanell, J., Kim, Y.-M., and Mendelsohn, J. (1998). Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825-2831.
10. Beerli, R.R., and Hynes, N.E. (1996). Epidermal growth factor-related peptide activate distinct subsets of ErbB receptors and differ in their biological activities. J. Biol. Chem. 271, 6071-6076.
11. Beerli, R.R., Wels, W., and Hynes, N.E. (1994). Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J. Biol. Chem. 269, 23931-23936.
12. Beerli, R., Graus-Porta, D., Woods-Cook, K., Chen, X., Yarden, Y., and Hynes, N.E. (1995). Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol. Cell. Biol. 15, 6496-6505.
13. Ben-Bassat, H., and Klein, B.Y. (2000). Inhibitors of tyrosine kinases in the treatment of psoriasis. Curr. Pharm. Des. 6, 933-942.
14. Chung, L.W. (1993). Implications of stromal-epithelial interaction in human prostate cancer growth, progression and differentiation. Semin. Cancer Biol. 4, 183-192.
15. Clynes, R.A., Towers, T.L., Presta, L.G., and Ravetch, J.V. (2000). Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6, 443-446.
16. Cobleigh, M.A., Vogel, C.L., Tripathy, D., Robert, N.J., Scholl, S., Fehrenbacher, L., Wolter, J., Paton, V., Shak, S., Lieberman, G., and Slamon, D.J. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648.
17. Craft, N., Shostak, Y., Carey, M., and Sawyers, C.L. (1999). A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 5, 280-285.
18. Cullen, K.J., and Lippman, M.E. (1992). Stromal-epithelial interactions in breast cancer. Cancer Treat. Res. 61, 413-431.
19. Cunha, G.R. (1994). Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer 74, 1030-1044.
20. deFazio, A., Chiew, Y.E., Sini, R.L., Janes, P.W., and Sutherland, R.L. (2000). Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int. J. Cancer 87, 487-498.
21. Duque, J.L., Adam, R.M., Mullen, J.S., Lin, J., Richie, J.P., and Freeman, M.R. (2001). Heparin-binding epidermal growth factor-like growth factor is an autocrine mediator of human prostate stromal cell growth in vitro. J. Urol. 165, 284-288.
22. Fendly, B.M., Winget, M., Hudziak, R.M., Lipari, M.T., Napier, M.A., and Ullrich, A. (1990). Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50, 1550-1558.
23. Fitzpatrick, V.D., Pisacane, P.I., Vandlen, R.L., and Sliwkowski, M.X. (1998). Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4. FEBS Lett. 431, 102-106.
24. Gibson, U.E.M., Heid, C.A., and Williams, P.M. (1996). A novel method for real time quantitative PCR. Genome Res. 6, 986-994.
25. Graus-Porta, D., Beerli, R.R., Daly, J.M., and Hynes, N.E. (1997). ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16, 1647-1655.
26. Grossmann, M.E., Huang, H., and Tindall, D.J. (2001). Androgen receptor signaling in androgen-refractory prostate cancer. J. Natl. Cancer Inst. 93, 1687-1697.
27. Guy, P.M., Platko, J.V., Cantley, L.C., Cerione, R.A., and Carraway, K.L., III. (1994). Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. USA 91, 8132-8136.
28. Heid, C.A., Stevens, J., Livak, K.J., and Williams, P.M. (1996). Real time quantitative PCR. Genome. Res. 6, 986-994.
29. Hidalgo, M., Siu, L.L., Nemunaitis, J., Rizzo, J., Hammond, L.A., Takimoto, C., Eckhardt, S.G., Tolcher, A., Britten, C.D., Denis, L., et al. (2001). Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19, 3267-3279.
30. Jones, J.T., Ballinger, M.D., Pisacane, P.I., Lofgren, J.A., Fairbrother, W.J., Wells, J.A., and Sliwkowski, M.X. (1998). Binding interaction of the heregulinβ EGF-domain with ErbB3 and ErbB4 receptors assessed by alanine scanning mutagenesis. J. Biol. Chem. 273, 11667-11674.
31. Jones, J.T., Akita, R.W., and Sliwkowski, M.X. (1999). Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett. 447, 227-231.
32. cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogen amplification with recurrence in prostatic adenocarcinomas. J. Clin. Oncol. 16, 1302-1309.
33. Kalmes, A., Vesti, B., Daum, G., Abraham, J.A., and Clowes, A.W. (2000). Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor. Circ. Res. 87, 92-98.
34. Karunagaran, D., Tzahar, E., Beerli, R.R., Chen, X., Graus-Porta, D., Ratzkin, B.J., Seger, R., Hynes, N.E., and Yarden, Y. (1996). ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J. 15, 254-264.
35. Kelley, R.F., O'Connell, M.P., Carter, P., Presta, L., Eigenbrot, C., Covarrubias, M., Snedecor, B., Bourell, J.H., and Vetterlein, D. (1992). Antigen binding thermodynamics and antiproliferatvie effects of chimeric and humanized anti-p185HER2 antibody Fab fragments. Biochemisty 31, 5434-5441.
36. Kim, H.-G., Kassis, J., Souto, J.C., Turner, T., and Wells, A. (1999). EGF receptor signaling in prostate morphogenisis and tumorigenesis. Histol. Histopathol. 14, 1175-1182.
37. Klapper, L.N., Glathe, S., Vaisman, N., Hynes, N.E., Andrews, G.C., Sela, M., and Yarden, Y. (1999). The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc. Natl. Acad. Sci. USA 96, 4995-5000.
38. Lenferink, A.E., Pinkas-Kramarski, R., van de Poll, M.L., van Vugt, M.J., Klapper, L.N., Tzahar, E., Waterman, H., Sela, M., van Zoelen, E.J., and Yarden, Y. (1998). Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J. 17, 3385-3397.
39. Lewis, G.D., Lofgren, J.A., McMurtrey, A.E., Nuijens, A., Fendly, B.M., Bauer, K.D., and Sliwkowski, M.X. (1996). Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res. 56, 1457-1465.
40. Marte, B.M., Graus-Porta, D., Jeschke, M., Fabbro, D., Hynes, N.E., and Taverna, D. (1995). NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells. Oncogene 10, 167-175.
41. Mendelsohn, J., and Baselga, J. (2000). The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550-6565.
42. Molina, M.A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J., and Baselga, J. (2001). Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61, 4744-4749.
43. Nagabhushan, M., Miller, C.M., Pretlow, T.P., Giaconia, J.M., Edgehouse, N.L., Schwartz, S., Kung, H.J., de Vere White, R.W., Gumerlock, P.H., Resnick, M.I., et al. (1996). CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res. 56, 3042-3046.
44. Olayioye, M.A., Graus-Porta, D., Beerli, R.R., Rohrer, J., Gay, B., and Hynes, N.E. (1998). ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol. Cell. Biol. 18, 5042-5051.
45. Osman, I., Scher, H.I., Drobnjak, M., Verbel, D., Morris, M., Agus, D., Ross, J.S., and Cordon-Cardo, C. (2001). HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin. Cancer Res. 7, 2643-2647.
46. Oxley, J.D., Winkler, M.H., Gillatt, D.A., and Peat, D.S. (2002). Her-2/neu oncogene amplification in clinically localised prostate cancer. J. Clin. Pathol. 55, 118-120.
47. Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., and Slamon, D. (1999). Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18, 2241-2251.
48. Pietras, R.J., Pegram, M.D., Finn, R.S., Maneval, D.A., and Slamon, D.J. (1998). Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17, 2235-2249.
49. Pinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B.J., Sela, M., and Yarden, Y. (1996a). Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 15, 2452-2467.
50. Pinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B.J., Sela, M., and Yarden, Y. (1996b). Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 15, 2452-2467.
51. Reese, D.M., Small, E.J., Magrane, G., Waldman, F.M., Chew, K., and Sudilovsky, D. (2001). HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am. J. Clin. Pathol. 116, 234-239.
52. Ross, J.S., Sheehan, C., Hayner-Buchan, A.M., Ambros, R.A., Kallakury, B.V., Kaufman, R., Fisher, H.A., and Muraca, P.J. (1997). HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Hum. Pathol. 28, 827-833.
53. Sadick, M.D., Sliwkowski, M.X., Nuijens, A., Bald, L., Chiang, N., Lofgren, J.A., and Wong, W.L.T. (1996). Analysis of heregulin-induced ErbB2 phosphorylation with a high throughput "Kinase Receptor Activation" (KIRA) ELISA. Anal. Biochem. 235, 207-214.
54. Savinainen, K.J., Saramaki, O.R., Linja, M.J., Bratt, O., Tammela, T.L., Isola, J.J., and Visakorpi, T. (2002). Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am. J. Pathol. 160, 339-345.
55. Schaefer, G., Fitzpatrick, V.D., and Sliwkowski, M.X. (1997). γ-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast tumor cell line, MDA-MB-175. Oncogene 15, 1385-1394.
56. Scher, H.I., Sarkis, A., Reuter, V., Cohen, D., Netto, G., Petrylak, D., Lianes, P., Fuks, Z., Mendelsohn, J., and Cordon-Cardo, C. (1995). Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin. Cancer Res. 1, 545-550.
57. Shawver, L., Slamon, D., and Ullrich, A. (2002). Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1, 117-123.
58. Shi, Y.A.N., Brands, F.H., Chatterjee, S., Feng, A.-C., Groshen, S., Schewe, J., Lieskovsky, G., and Cote, R.J. (2001). Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J. Urol. 166, 1514-1519.
59. Signoretti, S., Montironi, R., Manola, J., Altimari, A., Tam, C., Bubley, G., Balk, S., Thomas, G., Kaplan, I., Hlatky, L., et al. (2000). Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl. Cancer Inst. 92, 1918-1925.
60. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., and McGuire, W.L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
61. Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792.
62. Sliwkowski, M.X., Schaefer, G., Akita, R.W., Lofgren, J.A., Fitzpatrick, V.D., Nuijens, A., Fendly, B.M., Cerione, R.A., Vandlen, R.L., and Carraway, K.L., III. (1994). Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem. 269, 14661-14665.
63. Sliwkowski, M.X., Lofgren, J., Lewis, G.D., Hotaling, T.E., Fendly, B.M., and Fox, J.A. (1999). Nonclinical studies addressing the mechanism of action of trastuzumab (herceptin). Semin. Oncol. 26, Suppl 12, 60-70.
64. Soltoff, S.P., Carraway, K.L., III, Prigent, S.A., Gullick, W.G., and Cantley, L.C. (1994). ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol. Cell. Biol. 14, 3550-3558.
65. Torring, N., Jorgensen, P.E., Sorensen, B.S., and Nexo, E. (2000). Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res. 20, 91-95.
66. Tzahar, E., and Yarden, Y. (1998). The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim. Biophys. Acta 1377, M25-37.
67. Wainstein, M.A., He, F., Robinson, D., Kung, H.J., Schwartz, S., Giaconia, J.M., Edgehouse, N.L., Pretlow, T.P., Bodner, D.R., Kursh, E.D., et al. (1994). CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res. 54, 6049-6052.
68. Wallasch, C., Weiss, F.U., Niederfellner, G., Jallal, B., Issing, W., and Ullrich, A. (1995). Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J. 14, 4267-4275.
69. Wells, A. (1999). EGF receptor. Int. J. Biochem. Cell Biol. 31, 637-643.
70. Wen, Y., Hu, M.C., Makino, K., Spohn, B., Bartholomeusz, G., Yan, D.H., and Hung, M.C. (2000). HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 60, 6841-6845.
71. Woodburn, J.R. (1999). The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther. 82, 241-250.
72. Worthylake, R., Opresko, L.K., and Wiley, H.S. (1999). ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB2 and epidermal growth factor receptors. J. Biol. Chem. 274, 8865-8874.
73. Yarden, Y., and Sliwkowski, M.X. (2001). Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2, 127-137.
74. Yeh, S., Lin, H.-K., Kang, H.-Y., Thin, T.H., Lin, M.-F., and Chang, C. (1999). From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA 96, 5458-5463.